[go: up one dir, main page]

DE60105424D1 - Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden - Google Patents

Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden

Info

Publication number
DE60105424D1
DE60105424D1 DE60105424T DE60105424T DE60105424D1 DE 60105424 D1 DE60105424 D1 DE 60105424D1 DE 60105424 T DE60105424 T DE 60105424T DE 60105424 T DE60105424 T DE 60105424T DE 60105424 D1 DE60105424 D1 DE 60105424D1
Authority
DE
Germany
Prior art keywords
beta
methods
hepatitis virus
virus infections
delta hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60105424T
Other languages
English (en)
Other versions
DE60105424T2 (de
Inventor
Jean-Pierre Sommadossi
L Bryant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Idenix Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Cayman Ltd filed Critical Idenix Cayman Ltd
Publication of DE60105424D1 publication Critical patent/DE60105424D1/de
Application granted granted Critical
Publication of DE60105424T2 publication Critical patent/DE60105424T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60105424T 2000-05-26 2001-05-29 Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden Expired - Fee Related DE60105424T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20753800P 2000-05-26 2000-05-26
US207538P 2000-05-26
PCT/US2001/017301 WO2001091737A2 (en) 2000-05-26 2001-05-29 Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides

Publications (2)

Publication Number Publication Date
DE60105424D1 true DE60105424D1 (de) 2004-10-14
DE60105424T2 DE60105424T2 (de) 2005-09-22

Family

ID=22771005

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60105424T Expired - Fee Related DE60105424T2 (de) 2000-05-26 2001-05-29 Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden

Country Status (17)

Country Link
US (1) US6596700B2 (de)
EP (1) EP1292313B1 (de)
JP (1) JP2004513070A (de)
KR (1) KR100854398B1 (de)
CN (1) CN100490818C (de)
AT (1) ATE275406T1 (de)
AU (3) AU2001263484B2 (de)
BR (1) BR0111195A (de)
CA (1) CA2410488C (de)
DE (1) DE60105424T2 (de)
EA (1) EA005890B1 (de)
ES (1) ES2227203T3 (de)
IL (1) IL153078A0 (de)
MX (1) MXPA02011641A (de)
TR (1) TR200402565T4 (de)
WO (1) WO2001091737A2 (de)
ZA (2) ZA200210100B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA986614B (en) * 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
CN1257912C (zh) * 1998-08-10 2006-05-31 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β－L－2′－脱氧－核苷
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US20020056123A1 (en) * 2000-03-09 2002-05-09 Gad Liwerant Sharing a streaming video
ATE414520T1 (de) 2000-04-13 2008-12-15 Pharmasset Inc 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA007867B1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
US6787526B1 (en) * 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
KR100905221B1 (ko) 2000-10-18 2009-07-01 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
CN104193791A (zh) * 2002-06-28 2014-12-10 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003263412A1 (en) * 2002-06-28 2004-01-19 Centre National De La Recherche Scientifique (Cnrs) 1'-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
KR20080053419A (ko) * 2002-09-13 2008-06-12 이데닉스 (케이만) 리미티드 내성 ＨＢＶ 균주 치료용 β-Ｌ-2'-데옥시뉴클레오시드 및병용 요법
BR0315806A (pt) * 2002-10-31 2005-09-13 Metabasis Therapeutics Inc Fosfato diésteres cìclicos de 1,3-propano-1-aril diós e seu uso na preparação de pró-drogas
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
CN1303089C (zh) * 2002-11-19 2007-03-07 天津药物研究院 阿德福韦酯结晶形态及其制备方法
CN1330373C (zh) * 2002-12-02 2007-08-08 美德（江西）生物科技有限公司 含alfa－干扰素，阿地福韦和二脱氧氟硫代胞嘧啶的药物组合物
PL377287A1 (pl) * 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
PT1633766T (pt) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
AR054778A1 (es) 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
US7781576B2 (en) * 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9676797B2 (en) 2015-09-02 2017-06-13 Abbvie Inc. Anti-viral compounds
CA2794671C (en) 2010-03-31 2018-05-01 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
WO2012012776A1 (en) 2010-07-22 2012-01-26 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
CN103209987B (zh) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
EP2646453A1 (de) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Verbindungen
KR101880724B1 (ko) * 2010-12-10 2018-08-17 시그마팜 래보러토리즈, 엘엘씨 경구 활성 뉴클레오티드 유사체 또는 경구 활성 뉴클레오티드 유사체 전구약물의 고 안정성 조성물
KR20190075142A (ko) 2011-09-16 2019-06-28 길리애드 파마셋 엘엘씨 Hcv 치료 방법
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2794630A4 (de) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituierte phosphorthioat-nukleotidanaloga
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
HUE047777T2 (hu) 2013-01-31 2020-05-28 Gilead Pharmasset Llc Két vírusellenes vegyület kombinációs készítménye
US9901577B2 (en) * 2013-07-31 2018-02-27 Merck Patent Gmbh Oxoquinazolinyl-butanamide derivatives
EP3650014B1 (de) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Kombinationsformulierung von zwei antiviralen verbindungen
EP3105238A4 (de) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Organische verbindungen und deren verwendungen
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
MX389016B (es) 2015-06-17 2025-03-20 Univ Columbia Terapia con desoxinucleósidos para enfermedades generadas por grupos de nucleótidos desequilibrados, inclusive síndromes de agotamiento del adn mitocondrial.
CN108264524A (zh) * 2016-12-31 2018-07-10 正大天晴药业集团股份有限公司 恩曲他滨膦酸酯化合物
RU2644156C1 (ru) 2017-02-28 2018-02-08 Александр Васильевич Иващенко Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения
KR20190141747A (ko) 2017-05-01 2019-12-24 길리애드 사이언시즈, 인코포레이티드 (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
RU2662160C9 (ru) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
RU2662161C1 (ru) * 2017-08-11 2018-07-24 Васильевич Иващенко Александр Ингибитор входа вируса гепатита и фармацевтическая композиция для лечения гепатита
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
CN115362004B (zh) 2020-04-06 2026-01-09 吉利德科学公司 1’-氰基取代的碳核苷类似物的吸入制剂
WO2021243157A1 (en) 2020-05-29 2021-12-02 Gilead Sciences, Inc. Remdesivir treatment methods
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
EP4200301B1 (de) 2020-08-24 2025-02-26 Gilead Sciences, Inc. Phospholipidverbindungen und verwendungen davon
PT4204421T (pt) 2020-08-27 2024-06-25 Gilead Sciences Inc Compostos e métodos para o tratamento de infeções virais
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
TWI867455B (zh) 2022-03-02 2024-12-21 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
JP3693357B2 (ja) * 1993-04-09 2005-09-07 峯郎 実吉 逆転写酵素阻害剤
WO1996011204A1 (de) 1994-10-07 1996-04-18 Max-Delbrück-Centrum für Molekulare Medizin NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG
CN1257912C (zh) 1998-08-10 2006-05-31 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β－L－2′－脱氧－核苷

Also Published As

Publication number Publication date
TR200402565T4 (tr) 2004-12-21
US20020035085A1 (en) 2002-03-21
JP2004513070A (ja) 2004-04-30
WO2001091737A3 (en) 2002-05-30
EP1292313A2 (de) 2003-03-19
AU2006252214A1 (en) 2007-01-18
CN1444483A (zh) 2003-09-24
EA200201263A1 (ru) 2003-06-26
AU2001263484B2 (en) 2006-12-14
ZA200210100B (en) 2004-06-22
ATE275406T1 (de) 2004-09-15
ZA200404304B (en) 2005-03-30
KR20030031487A (ko) 2003-04-21
CN100490818C (zh) 2009-05-27
AU6348401A (en) 2001-12-11
WO2001091737A2 (en) 2001-12-06
CA2410488C (en) 2009-10-27
HK1050999A1 (en) 2003-07-18
EP1292313B1 (de) 2004-09-08
IL153078A0 (en) 2003-06-24
CA2410488A1 (en) 2001-12-06
US6596700B2 (en) 2003-07-22
ES2227203T3 (es) 2005-04-01
EA005890B1 (ru) 2005-06-30
MXPA02011641A (es) 2004-07-30
BR0111195A (pt) 2004-07-20
KR100854398B1 (ko) 2008-08-26
DE60105424T2 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
DE60105424D1 (de) Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
MXPA02011635A (es) Metodos y composiciones para el tratamiento del virus de la hepatitis c.
ATE395922T1 (de) Lipid-analoge zur behandlung von viralen infektionen
EA200201262A1 (ru) Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
WO2003026589A3 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
ATE326236T1 (de) Hpv-e7 zur behandlung von menschlichem papillomavirus
BR0110023A (pt) Derivados de nucleosìdeo 3'-ou-2' substituìdos para tratamento de infecções por vìrus da hepatite
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
ATE339211T1 (de) L-fmau zur behandlung von hepatitis-delta-virus- infizierung
ATE284408T1 (de) Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten
ZA991029B (en) Composition and methods for treatment of hiv infections.
ATE100318T1 (de) Verwendung von chinolyl- und isochinolyloxazol-2- onen zur herstellung eines arzneimittels zur verhinderung der ansteckungsfaehigkeit von mit glykoproteinen umhuellten viren.
RS20120367A3 (en) METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH

8339 Ceased/non-payment of the annual fee